Page 1551 - Williams Hematology ( PDFDrive )

1526 Part XI: Malignant Lymphoid Diseases <CN>: <ct> PB

245. Ritchey AK, Pollock BH, Lauer SJ, et al: Improved survival of children with isolated 269. Waber DP, Turek J, Catania L, et al: Neuropsychological outcomes from a randomized
CNS relapse of acute lymphoblastic leukemia: A Pediatric Oncology Group study. J Clin trial of triple intrathecal chemotherapy compared with 18 Gy cranial radiation as CNS
Oncol 17:3745, 1999. treatment in acute lymphoblastic leukemia: Findings from Dana-Farber Cancer Insti-
246. Barredo J, Devidas M, Lauer SJ, et al: Isolated CNS relapse of acute lymphoblastic leu- tute ALL Consortium Protocol 95–01. J Clin Oncol 25:4914, 2007.
kemia treated with intensive systemic chemotherapy and delayed CNS radiation: A 270. Leung W, Rose SR, Zhou Y, et al: Outcomes of growth hormone replacement therapy in
Pediatric Oncology Group study. J Clin Oncol 24:3142, 2006. survivors of childhood acute lymphoblastic leukemia. J Clin Oncol 20:2959, 2002.
247. Wofford MM, Smith SD, Shuster JJ, et al: Treatment of occult or late overt testicular 271. Perkins SM, Dewees T, Shinohara ET, et al: Risk of subsequent malignancies in survi-
relapse in children with acute lymphoblastic leukemia: A Pediatric Oncology Group vors of childhood leukemia. J Cancer Surviv 7:544, 2013.
study. J Clin Oncol 10:624, 1992. 272. Schmiegelow K, Levinsen MF, Attarbaschi A, et al: Second malignant neoplasms after
248. Finklestein JZ, Miller DR, Feusner J, et al: Treatment of overt isolated testicular relapse treatment of childhood acute lymphoblastic leukemia. J Clin Oncol 31:2469, 2013.
in children on therapy for acute lymphoblastic leukemia. A report from the Children’s 273. Walter AW, Hancock ML, Pui CH, et al: Secondary brain tumors in children treated
Cancer Group. Cancer 73:219, 1994. for acute lymphoblastic leukemia at St. Jude Children’s Research Hospital. J Clin Oncol
249. van den Berg H, Langeveld NE, Veenhof CH, Behrendt H: Treatment of isolated testic- 16:3761, 1998.
ular recurrence of acute lymphoblastic leukemia without radiotherapy. Report from the 274. Pui CH, Ribeiro RC, Hancock ML, et al: Acute myeloid leukemia in children treated
Dutch Late Effects Study Group. Cancer 79:2257, 1997. with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med 325:1682,
250. Roberson JR, Raju S, Shelso J, et al: Diabetic ketoacidosis during therapy for childhood 1991.
acute lymphoblastic leukemia. Pediatr Blood Cancer 50:1207, 2008. 275. Kenney LB, Nicholson HS, Brasseux C, et al: Birth defects in offspring of adult survi-
251. Pui CH, Burghen GA, Bowman WP, Aur RJ: Risk factors for hyperglycemia in children vors of childhood acute lymphoblastic leukemia. A Children’s Cancer Group/National
with leukemia receiving l-asparaginase and prednisone. J Pediatr 99:46, 1981. Institutes of Health Report. Cancer 78:169, 1996.
252. Laningham FH, Kun LE, Reddick, et al: Childhood central nervous system leukemia: 276. Sankila R, Olsen JH, Anderson H, et al: Risk of cancer among offspring of childhood-
Historical perspectives, current therapy, and acute neurological sequelae. Neuroradiol- cancer survivors. Association of the Nordic Cancer Registries and the Nordic Society of
ogy 49:873, 2007. Paediatric Haematology and Oncology. N Engl J Med 338:1339, 1998.
253. Bhojwani D, Sabin ND, Pei D, et al: Methotrexate-induced neurotoxicity and leukoen- 277. Pui CH, Mullighan CG, Evans WE, Relling MV: Pediatric acute lymphoblastic leuke-
cephalopathy in childhood acute lymphoblastic leukemia. J Clin Oncol 32:949, 2014. mia: Where are we going and how do we get there? Blood 120:1165, 2012.
254. Kadan-Lottick NS, Dinu I, Wasilewski-Masker K, et al: Osteonecrosis in adult survivors 278. Creutzig U1, van den Heuvel-Eibrink MM, Gibson B,, et al; AML Committee of the
of childhood cancer: A report from the childhood cancer survivor study. J Clin Oncol International BFM Study Group: Diagnosis and management of acute myeloid leuke-
26:3038, 2008. mia in children and adolescents: Recommendations from an international expert panel.
255. Rai SN, Hudson MM, McCammon E, et al: Implementing an intervention to improve Blood 120:3187, 2012.
bone mineral density in survivors of childhood acute lymphoblastic leukemia: BONEII, 279. Fielding AK, Banerjee L, Marks DI: Recent developments in the management of T-cell pre-
a prospective placebo-controlled double-blind randomized interventional longitudinal cursor acute lymphoblastic leukemia/lymphoma. Curr Hematol Malig Rep 7:160, 2012.
study design. Contemp Clin Trials 29:711, 2008. 280. Freedman AS, Friedberg JW: Treatment of Burkitt leukemia/lymphoma in adults, in
256. Thomas IH, Donohue JE, Ness KK, et al: Bone mineral density in your adult survivors UpToDate, edited by Post TW TW. UpToDate, Waltham, MA. http://www.uptodate.
of acute lymphoblastic leukemia. Cancer 113:3248, 2008. com/contents/treatment-of-burkitt-leukemia-lymphoma-in-adults. (Accessed on
257. Te Winkel ML, Pieters R, Wind EJ, et al: Management and treatment of osteonecrosis August 07, 2015.)
in children and adolescents with acute lymphoblastic leukemia. Haematologica 99:430, 281. Bhatia S, Sather HN, Heerema NA, et al: Racial and ethnic differences in survival of
2014. children with acute lymphoblastic leukemia. Blood 100:1957, 2002.
258. Grenier MA, Lipshultz SE: Epidemiology of anthracycline cardiotoxicity in children 282. Kadan-Lottick NS, Ness KK, Bhatia S, Gurney JG: Survival variability by race and eth-
and adults. Semin Oncol 25:72, 1998. nicity in childhood acute lymphoblastic leukemia. JAMA 290:2008, 2003.
259. Childhood Acute Lymphoblastic Leukaemia Collaborative Group (CALLCG): Benefi- 283. Pui CH, Sandlund JT, Pei D, et al: Results of therapy for acute lymphoblastic leukemia
cial and harmful effects of anthracyclines in the treatment of childhood acute lympho- in black and white children. JAMA 290:2001, 2003.
blastic leukaemia: A systematic review and meta-analysis. Br J Haematol 145:376, 2009. 284. Breit S, Stanulla M, Flohr T, et al: Activating NOTCH1 mutations predict favorable
260. Zerra P, Cochran TR, Franco VI, Lipshultz SE: An expert opinion on pharmacologic early treatment response and long-term outcome in childhood precursor T-cell lym-
approaches to reducing the cardiotoxicity of childhood acute lymphoblastic leukemia phoblastic leukemia. Blood 108:1151, 2009.
therapies. Expert Opin Pharmacother 14:1497, 2013. 285. Asnafi V, Buzyn A, Le NS, et al: NOTCH1/FBXW7 mutation identifies a large sub-
261. Levitt GA, Dorup I, Sorensen K, Sullivan I: Does anthracycline administration by infu- group with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): A
sion in children affect late cardiotoxicity? Br J Haematol 124:463, 2004. Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study. Blood
262. Lipshultz S, Lipsitz SR, Sallan SE, et al: Chronic progressive cardiac dysfunction 113:3918, 2009.
years after doxorubicin therapy for acute lymphoblastic leukemia. J Clin Oncol 23:2629, 286. Abdelali RB, Asnafi V, Leguay T, et al: Pediatric-inspired intensified therapy of adult
2005. T-ALL reveals the favourable outcome of NOTCH/FBXW7 mutations, but not of low
263. Lipshultz SE, Rifai N, Dalton VM, et al: The effect of dexrazoxane on myocardial injury ERG/BAALC expression: A GRAALL study. Blood 118:5099, 2011.
in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 287. Raff T, Gokbuget N, Luschen S, et al: Molecular relapse in adult standard-risk ALL
351:145, 2004. patients detected by prospective MRD monitoring during and after maintenance treat-
264. Sieswerda E, van Dalen EC, Postma A, et al: Medical interventions for treating anthra- ment: Data from the GMALL 06/99 and 07/03 trials. Blood 109:910, 2007.
cycline-induced symptomatic and asymptomatic cardiotoxicity during and after treat- 288. Coustan-Smith E, Sancho J, Hancock ML, et al: Use of peripheral blood instead of bone
ment for childhood cancer. Cochrane Database Syst Rev (9):CD008011, 2011. marrow to monitor residual disease in children with acute lymphoblastic leukemia.
265. Oeffinger KC, Mertesn AC, Sklar CA, et al: Chronic health conditions in adult survivors Blood 100:2399, 2002.
of childhood cancer. N Engl J Med 355:1572, 2006. 289. Bader P, Kreyenberg H, Henze GHR, et al: Prognostic value of minimal resid-
266. Pui CH, Cheng C, Leung W, et al: Extended follow-up of long-term survivors of child- ual disease quantification before allogeneic stem-cell transplantation in relapsed
hood acute lymphoblastic leukemia. N Engl J Med 349:640, 2003. childhood acute lymphoblastic leukemia: The ALL-REZ BFM Study Group. J Clin
267. Hijiya N, Hudson MM, Lensing S, et al: Cumulative incidence of secondary neoplasms Oncol 27:377, 2008.
as a first event after childhood acute lymphoblastic leukemia. JAMA 297:1207, 2007. 290. Gokbuget N, Stanze D, Beck J, et al: Outcome of relapsed adult lymphoblastic leukemia
268. Geenen MM, Cardous-Ubbink MC, Kremer LCM, et al: Medical assessment of adverse depends on response to salvage chemotherapy, prognostic factors, and performance of
health outcomes in long-term survivors of childhood cancer. JAMA 297:2705, 2007. stem cell transplantation. Blood 120:2032, 2012.

Kaushansky_chapter 91_p1505-1526.indd 1526 9/21/15 12:20 PM